FMP

FMP

Enter

AFMD - Affimed N.V.

Financial Summary of Affimed N.V.(AFMD), Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing canc

photo-url-https://financialmodelingprep.com/image-stock/AFMD.png

Affimed N.V.

AFMD

NASDAQ

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

5.15 USD

-0.29 (-5.63%)

About

ceo

Dr. Andreas Harstrick M.D.

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid ...

CIK

0001608390

ISIN

NL0015001ZQ0

CUSIP

N01045108

Address

Technologiepark

Phone

49 6221 6743 60

Country

DE

Employee

76

IPO Date

Sep 12, 2014

Summary

CIK

0001608390

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

N01045108

ISIN

NL0015001ZQ0

Country

DE

Price

5.15

Beta

2.12

Volume Avg.

724.7k

Market Cap

78.42M

Shares

-

52-Week

0.2235-8.95

DCF

-3.89

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-0.76

P/B

-

Website

https://www.affimed.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest AFMD News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep